Skip to main content
SpringerLink
Log in

Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study

  • SPECIAL ISSUE ARTICLE
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The purpose of this study was to evaluate the efficacy of postoperative adjuvant chemotherapy with FOLFOX regimen on the outcome after LT for HCC patients who did not meet the Milan criteria. Ninety-five consecutive HCC patients with liver cirrhosis undergoing LT were enrolled. Fifty-eight who did not meet the Milan criteria were randomized to open-label treatment with or without adjuvant chemotherapy after LT (n = 29/group). The FOLFOX chemotherapy protocol comprised 3-week cycles of oxaliplatin 100 mg/m2 on day 1, leucovorin (calcium folinate, CF) 200 mg/m2 on day 1 followed by 3-day, and 5-fluorouracil (5-FU) 2000 mg/m2 as a 48-h continuous infusion, for up to six courses in the 1st year after transplantation. Median survival was extended by 4.57 months by combination chemotherapy. The 1- and 3-year survival rates were 89.7% and 79.3% with chemotherapy versus 69.0% and 62.1% without chemotherapy. The cumulative 1-year survival was significantly increased by chemotherapy (log-rank test, P = 0.043). The 6-month tumor-free survival rate was 24.1% higher with chemotherapy than without. The recurrence rate after LT was significantly different between the two groups at 6 months (P = 0.036), but not at 3 years (P = 0.102). The chemotherapy regimen was generally well tolerated. Post-LT adjuvant chemotherapy with oxaliplatin/5-FU/CF could not prevent tumor recurrence post-LT but may contribute to improve the survival of HCC patients who do not meet the Milan criteria. These results should be verified in a larger sample with a longer follow-up period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271–285

    Article  PubMed  CAS  Google Scholar 

  2. Poon RTP, Fan ST, Wong J (2000) Risk factors prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24

    Article  Google Scholar 

  3. Coelho GR, Vasconcelos KF, Vasconcelos JB et al (2009) Orthotopic liver transplantation for hepatocellular carcinoma: one center’s experience in the Northeast of Brazil. Transplant Proc 41:1740–1742

    Article  PubMed  CAS  Google Scholar 

  4. Hertl M, Cosimi AB (2005) Liver transplantation for malignancy. Oncologist 10:269–281

    Article  PubMed  Google Scholar 

  5. Varona MA, Del Pino JM, Barrera M et al (2009) Hepatocellular carcinoma and liver transplantation: a 12-year experience. Transplant Proc 41:1005–1008

    Article  PubMed  CAS  Google Scholar 

  6. Chen GH (2009) Liver transplantation in China: retrospect and prospect. Chin Med J 122:2229–2230

    PubMed  Google Scholar 

  7. Fernandez JA, Robles R, Marin C et al (2003) Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 35:1818–1820

    Article  PubMed  CAS  Google Scholar 

  8. Chu F, Morris DL (2006) Single centre experience of liver resection for hepatocellular carcinoma in patients outside transplant criteria. Eur J Surg Oncol 32:568–572

    PubMed  CAS  Google Scholar 

  9. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

    Article  PubMed  CAS  Google Scholar 

  10. Yao FY, Ferrell L, Bass NM et al (2002) Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8:765–774

    Article  PubMed  Google Scholar 

  11. Gondolesi GE, Roayaie S, Muñoz L et al (2004) Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 239:142–149

    Article  PubMed  Google Scholar 

  12. Coriat R, Mir O, Cessot A et al (2010) Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs Aug 27 [Epub ahead of print]

  13. Shimoda M, Ghobrial RM, Carmody IC et al (2004) Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 10:1478–1486

    Article  PubMed  Google Scholar 

  14. Marsh JW, Dvorchik I, Subotin M et al (1997) The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 26:444–450

    Article  PubMed  CAS  Google Scholar 

  15. Gondolesi GE, Roayaie S, Muñoz L et al (2006) Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc 38:2495–2498

    Article  Google Scholar 

  16. Kwok PC, Lam TW, Lam PW et al (2003) Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. J Gastroenterol Hepatol 18:450–455

    Article  PubMed  CAS  Google Scholar 

  17. Ono T, Yamanoi A, El N et al (2001) Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 91:2378–2385

    Article  PubMed  CAS  Google Scholar 

  18. Hsieh CB, Chou SJ, Shih ML et al (2008) Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 34:906–910

    PubMed  Google Scholar 

  19. Xia Y, Qiu Y, Li J et al (2010) Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 17:3137–3144

    Article  PubMed  Google Scholar 

  20. Xu J, Zhong Y, Weixin N et al (2007) Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 245:583–590

    Article  PubMed  Google Scholar 

  21. Ragnhammar P, Hafström L, Nygren P et al (2001) Swedish council of technology assessment in health care. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282–308

    Article  PubMed  CAS  Google Scholar 

  22. Trojan J, Lubomierski N, Lehnert T et al (2008) Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Z Gastroenterol 46:776–779

    Article  PubMed  CAS  Google Scholar 

  23. Poggi G, Quaretti P, Minoia C et al (2008) Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 28:3835–3842

    PubMed  CAS  Google Scholar 

  24. Uhm JE, Park JO, Lee J et al (2009) A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic vchemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 63:929–935

    Article  PubMed  CAS  Google Scholar 

  25. Li S, Niu Z, Tian H et al (2007) Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 54:218–223

    PubMed  CAS  Google Scholar 

  26. Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182–194

    Article  PubMed  Google Scholar 

  27. Wang GQ, Wan DS, Zhou ZW et al (2007) Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis. Ai Zheng 26:411–414

    PubMed  Google Scholar 

  28. Raimondo ML, Burroughs AK (2002) Single-agent immunosuppression after liver transplantation: what is possible? Drugs 62:1587–1597

    Article  PubMed  CAS  Google Scholar 

  29. Tobinai K, Kohno A, Shimada Y et al (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23:250–257

    PubMed  CAS  Google Scholar 

  30. Yang BS, Ma YJ, Wang Y et al (2007) Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure. World J Gastroenterol 133:462–466

    Google Scholar 

  31. Alp MH, Hickman R (1987) The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure. J Hepatol 4:99–107

    Article  PubMed  CAS  Google Scholar 

  32. Sutcliffe R, Maguire D, Murphy P et al (2005) Detection and clinical significance of bone marrow micrometastases in patients undergoing liver transplantation for hepatocellular carcinoma. Transplantation 80:88–94

    Article  PubMed  Google Scholar 

  33. Olthoff KM, Rosove MH, Shackleton CR et al (1995) Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 221:734–743

    Article  PubMed  CAS  Google Scholar 

  34. Huang J, He X, Chen G et al (2002) Liver transplantation at the Sun Yat-Sen University of Medical Sciences in China. Chin Med J 115:543–548

    PubMed  Google Scholar 

  35. Roayaie S, Frischer JS, Emre SH et al (2002) Long term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinoma larger than 5 centimeters. Ann Surg 235:533–539

    Article  PubMed  Google Scholar 

  36. Qin S, Bai Y, Ye S et al (2010) Thongprasert, Y. Chao, K, Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients, Journal of Clinical Oncology. 2010 ASCO Annual Meeting Proceedings. 28 suppl (May 20 Supplement) 4008

  37. Cheng A-L, Kang Y-K, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  PubMed  CAS  Google Scholar 

  38. Lee JO, Kim DY, Lim JH et al (2009) Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 24:800–805

    Article  PubMed  CAS  Google Scholar 

  39. Vexler AM, Mou X, Gabizon AA et al (1995) Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. Int J Cancer 60:611–615

    Article  PubMed  CAS  Google Scholar 

  40. Boucher E, Corbinais S, Brissot P et al (2002) Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 50:305–308

    Article  PubMed  CAS  Google Scholar 

  41. Al-Batran SE, Atmaca A, Hegewisch-Becker S et al (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658–663

    Article  PubMed  CAS  Google Scholar 

  42. Louvet C, André T, Tigaud JM et al (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543–4548

    Article  PubMed  CAS  Google Scholar 

  43. Gerard JP, Chapet O, Nemoz C et al (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21:1119–1124

    Article  PubMed  Google Scholar 

  44. Pettengell R, Aapro M, Brusamolino E et al (2009) Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. Clin Drug Investig 29:491–513

    Article  PubMed  CAS  Google Scholar 

  45. Liongue C, Wright C, Russell AP et al (2009) Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int J Biochem Cell Biol 41:2372–2375

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Liver Transplantation, General Hospital of Chinese People’s Armed Police Force, 69 Yongding Road, Haidian District, Beijing, 100039, China

    Qing Zhang, Hong Chen, Yunjin Zang, Xinguo Chen, Weilong Zou, Letian Wang & Zhong-yang Shen

  2. Department of Transplant Surgery, Tianjin First Central Hospital, Tianjin, 300192, China

    Zhong-yang Shen

  3. Shaanxi Carcinoma Hospital, Xi’an, Shannxi, 710061, China

    Qin Li

Authors
  1. Qing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yunjin Zang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xinguo Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weilong Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Letian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhong-yang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhong-yang Shen.

Additional information

Qing Zhang and Hong Chen authors contributed equally to this work

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Q., Chen, H., Li, Q. et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs 29, 1360–1369 (2011). https://doi.org/10.1007/s10637-011-9726-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9726-1

Keywords

Search

Navigation